StageZero Life Sciences
  • About
    • Our Story
    • Board of Directors
    • Partners
    • Library
    • Programs >
      • Telehealth
      • Employers
      • Firefighters
      • Executive Health
  • Our Science
    • The Sentinel Principle
    • Aristotle
    • ColonSentry Science
    • Publications
  • Covid-19 Testing
    • Covid-19-PCR-Saliva
    • Covid-19-PCR
    • Covid-19-Antibody
    • Respiratory Panel + COVID-19
    • Covid-19-Employers
    • Covid-19-PhysicianEnrollment
    • Frequently Asked Questions
  • Cancer Testing
    • ColonSentry Test
    • Prostate Health Index
    • BreastSentry
    • Purchase Tests
  • Physicians
    • Physician Portal
    • Establish an Account
    • Order Supplies
    • Copia Login
  • INVESTORS
    • Investor Relations
    • Press Releases
    • Events
  • Contact
    • Customer Support
    • Corporate HQ
    • Careers
    • Bill Payment

​​ColonSentry®

Harnessing the Power of Gene Expression 
for Early Colorectal Cancer Detection

ColonSentry®

The First Liquid Biopsy for Colorectal Cancer Detection
ColonSentry® is a proprietary liquid biopsy test that uses advanced gene expression (mRNA) technology for the early identification of Colorectal Cancer (CRC). ​ColonSentry, was the first liquid biopsy for CRC, using our patented Sentinel Principle Technology Platform (1)and has been used on more than 100,000 patients nationwide. (2)
Validation
  • 9,000+ Patient Study North America (4)
  • 100,000+ Tests Performed in U.S. (2)
  • Finds Right & Left Sided Cancers (4)​
Clinical Utility
  • ColonSentry requires a simple, in-office blood draw.
  • If the ColonSentry score is elevated in a patient at average risk, there is an increased probability the patient may have a pre-cancerous lesion or colorectal cancer. (3)
  • ​Blood tests have a greater than 95% in-office compliance rate that motivates patients to comply with CRC screening. (6)
  • ColonSentry, in advance of Colonoscopy finds 2.1-4.7x more colorectal cancers (3)​
For Patients
For Physicians
Picture

​"The clinical utility of ColonSentry is significant. A routine blood test for patients who have yet to comply with any form of colorectal cancer screening can be a game-changer in identifying those at elevated risk for the disease and motivating them to have their colonoscopy. In addition, routine use of a blood test that detects both left-sided and right-sided lesions can increase the effectiveness of colorectal cancer screening by revealing the potential presence of neoplasms in advance of colonoscopy."

- Robert Burakoff, MD, Site Chief for the Division of Gastroenterology and Hepatology at New York-Presbyterian Lower Manhattan Hospital and Weill Cornell Medicine, 




Picture
The Science 

The ColonSentry® test uses quantitative real-time polymerase chain reaction (RT-PCR) to measure the RNA transcript expression of seven biomarker genes in a whole blood sample. Expression levels of six genes—ANXA3, CLEC4D, LMNB1, PRRG4, TNFAIP6, and VNN1—are each paired with the expression level of a reference gene, IL2RB, to create a genetic signature by which patients can be stratified for CRC risk. ​(3)

​ColonSentry
® specifically measures gene expression in whole blood. Tumors are known to affect the gene expression profiles of circulating leukocytes, including both myeloid cells (monocytes, macrophages, etc.) and lymphocytes (T cells, B cells, and natural killer cells).This occurs due to a unique interaction between tumor cells and the immune system that has been referred to as “cancer immunoediting.” Immunoediting comprises three stages: elimination (in which the immune system identifies cancerous and/or precancerous cells and attempts to eradicate them), equilibrium (in which the surviving tumor cells begin mutating rapidly under selection pressure from immune-system-mediated attacks), and escape (in which tumor cells that have acquired resistance proliferate uncontrollably, leading to tumor progression). ​(5)

PUblications

References
  1. Liew CC, Ma J, Tang HC, et al. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med. 2006  Mar;147(3):126-32. 
  2. Chao S, PilcZ T, Stamtiou D, et al. Stability of the ColonSentry Colon Cancer Risk Stratfication Test. Int. J Dis Markers. 2019 IJDM-101 DOI: 10.29011/IJDM-101-100001
  3. Marshall KW, Mohr S, Khettabi FE, et al. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer. 2010 Mar 1;126(5):1177-86. 
  4. Chao, S et al.  Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case–control study.  Journal of Experimental & Clinical Cancer Research 2013, 32:44
  5. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
  6.  Liles, E. et al.  Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial. Cancer Treatment and Research Communications 10 (2017) 27–31.
Picture
30-70 East Beaver Creek Road
Richmond Hill, Ontario L4B 3B2

8751 Park Central Drive, Suite 200
Richmond, VA 23227
​TEL: 855.420.7140


Notice of Privacy Practices | Terms & Conditions | Privacy Statement & Policy | Licensing & Accreditation
  • About
    • Our Story
    • Board of Directors
    • Partners
    • Library
    • Programs >
      • Telehealth
      • Employers
      • Firefighters
      • Executive Health
  • Our Science
    • The Sentinel Principle
    • Aristotle
    • ColonSentry Science
    • Publications
  • Covid-19 Testing
    • Covid-19-PCR-Saliva
    • Covid-19-PCR
    • Covid-19-Antibody
    • Respiratory Panel + COVID-19
    • Covid-19-Employers
    • Covid-19-PhysicianEnrollment
    • Frequently Asked Questions
  • Cancer Testing
    • ColonSentry Test
    • Prostate Health Index
    • BreastSentry
    • Purchase Tests
  • Physicians
    • Physician Portal
    • Establish an Account
    • Order Supplies
    • Copia Login
  • INVESTORS
    • Investor Relations
    • Press Releases
    • Events
  • Contact
    • Customer Support
    • Corporate HQ
    • Careers
    • Bill Payment